Special Issue "Metal-Based Drugs: Updates and Perspectives"

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: 31 August 2019

Special Issue Editors

Guest Editor
Prof. Daniela Montesarchio

Department of Chemical Sciences, University of Naples Federico II, via Cintia 4, 80126 Naples, Italy
Website | E-Mail
Interests: Oligonucleotides; Nucleoside analogues; Unusual structures of DNA; G-quadruplex; Ru(III)-complexes; Pt(II)-complexes; Metal–DNA interactions; Small Molecule–DNA interactions
Guest Editor
Dr. Domenica Musumeci

Department of Chemical Sciences, University of Naples Federico II, via Cintia 4, 80126 Naples, Italy
Website | E-Mail
Interests: Oligonucleotide analogues; PNA; Nucleopeptides; Peptidomimetics; Metal-based drugs; Ru(III)-complexes; Pt(II)-complexes; Metal–DNA interactions; Small Molecule–DNA interactions

Special Issue Information

Dear Colleagues,

the pharmaceutical potential of metals and their derivatives has been recognized for millennia in very different cultures, and with the advent of modern medicine, several metal-based drugs have been approved in clinic as effective therapeutic tools. Indeed, a large variety of metal compounds show significant bioactivity against a range of diseases, from the well-known anticancer activity of Pt(II)-complexes to the use of gold derivatives for the treatment of rheumatoid arthritis, just to name a few. Metal-based compounds can display an impressive chemical diversity, accompanied by a wide, easily and finely tunable reactivity, which allow their application as therapeutic and diagnostic tools in medicinal chemistry that is not readily accessible to the usual organic compounds.

This Special Issue of Pharmaceuticals on “Metal-Based Drugs: Updates and Perspectives” will include both regular articles and reviews focused on the most recent advances in the research into metals used in medicine, highlighting their pharmacological and diagnostic applications in several diseases. The major focus will be on the design, synthesis and optimization of novel complexes with higher efficacy and reduced toxic side effects compared to already existing metal-based drugs, on studies dealing with their mechanisms of action, the identification of their in vivo target, and approaches to validate their utility, along with their in vivo delivery, also taking advantage of specific or non-specific carriers (nanoparticles, liposomes, etc.).

With the aim of offering a dedicated forum open to all scientists engaged in this interdisciplinary research field, we particularly welcome contributions dealing with:

  • Metal-based complexes as therapeutic tools

Metallodrugs (design, synthesis, characterization, preclinical evaluation, pharmacokinetic studies, etc.) for the treatment of diseases, particularly with applications as:

anticancer, antimicrobial, antiparasitic, antibiotic, antiviral, anti-inflammatory, antiarthritic, antidiabetes, psychotropic, metallodrugs for the treatment of cardiovascular disorders, of metabolic diseases, of rare diseases, etc.

  • Metal-based complexes as diagnostic tools

Among others, diagnostic radiopharmaceuticals are powerful tools in the diagnosis of cancer, cardiological disorders, infections, kidney or liver abnormalities, neurological disorders, etc.

  • Studies of the mechanism of action of metallodrugs, with a special focus on the elucidation of their molecular targets
  • Studies on the biodistribution and fate of metallodrugs under in vivo conditions, including the physiological effects and toxicity issues.

Prof. Daniela Montesarchio
Dr. Domenica Musumeci
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 850 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • metallodrugs
  • anticancer
  • antimicrobial
  • antiparasitic
  • antibiotic
  • antiviral
  • anti-inflammatory
  • antiarthritic
  • antidiabetes
  • psychotropic
  • cardiovascular disorders
  • metabolic diseases
  • rare diseases, etc.

Published Papers

This special issue is now open for submission.
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top